The bipartisan Biosimilar Red Tape Elimination Act would cut drug prices and increase competition in the pharmaceutical ...

Sen. Mike Lee (R-UT) has proposed bipartisan legislation to cut drug prices and bureaucratic red tape for American consumers.

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference products. These differences may affect ...

Key pharma stocks, including Granules India and Gland Pharma, have shown substantial recovery, with the Nifty Pharma index ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. We sell ...

Dr Reddy's Lab shares jumped 4% on June 5, making it the top gainer on the Nifty 50. This surge followed the announcement of ...

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...